Key Record Dates
| ClinicalTrials.gov Identifier: | NCT03976375 |
|---|---|
| Brief Title: | Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008) |
| First Submitted : | June 3, 2019 |
| First Submitted that Met QC Criteria : | June 3, 2019 |
| First Posted : | June 6, 2019 |
| Last Update Submitted that Met QC Criteria : | September 1, 2022 |
| Last Update Posted : | September 2, 2022 |